Fiona K. Middleton

Targeting the S and G2 checkpoint to treat cancer.

N. Curtin, P. Stephens, Tao Chen, 2012, Drug discovery today.

Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio‐resistance in breast cancer

I. Ellis, A. Green, N. Curtin, 2016, Molecular oncology.

Untangling the ATR‐CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer

Graham Ball, Devika Agarwal, Ian O Ellis, 2015, Molecular oncology.

Development of pharmacodynamic biomarkers for ATR inhibitors

N. Curtin, P. Reaper, Tao Chen, 2015, Molecular oncology.

ATR as a Therapeutic Target

N. Curtin, Fiona K. Middleton, 2013 .

Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition

N. Curtin, J. Allan, M. Wade, 2015, Oncotarget.

The Impact of p53 Dysfunction in ATR Inhibitor Cytotoxicity and Chemo- and Radiosensitisation

N. Curtin, Fiona K. Middleton, J. Pollard, 2018, Cancers.